Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management-Reference-Cited by-同舟云学术

Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management

Published:2022-04 Issue:2 Volume:49 Page:119-129
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

van Leeuwen Roelof W.F.^ORCID,le Comte Marianne,Reyners Anna K.L.,van den Tweel Annemieke,van Vlijmen Bas,Kwee Wilma,Wensveen Brigit,Steeghs Neeltje^ORCID,Visser Otto,van Gelder Teun,Jansman Frank G.A.^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference27 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Signaleringscommissie Kanker KWF Kankerbestrijding. Kanker in Nederland tot 2020. Trends en prognoses (2011).

3. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients;Alkan;Support Care Cancer,2017

4. Polypharmacy and potentially inappropriate medication use in geriatric oncology;Sharma;J Geriatr Oncol,2016

5. Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs;Van Leeuwen;Br. J. Cancer,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration;Cancer Treatment Reviews;2024-09

2. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments;Critical Reviews in Oncology/Hematology;2024-08

3. Dynamic monitoring of the cytotoxic effects of Cousinia iconica extracts on A549 and RL95-2 cells using the xCELLigence RTCA system;Indian Journal of Traditional Knowledge;2024-06-20

4. Mise en place de consultations pharmaceutiques d’initiation en oncologie digestive dans un centre hospitalo-universitaire : bilan à un an;Bulletin du Cancer;2024-04

5. Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management;Blood Reviews;2024-03